Enzo Biochem (ENZ) Gets NY DoH Approval for ColonSentry Test
Enzo Biochem, Inc. (NYSE: ENZ) today announced that the New York State Department of Health has approved Enzo Clinical Labs’ use of the ColonSentry test for providing an assessment of a patient’s risk of having colorectal cancer. The ColonSentry test was originally developed by GeneNews and requires only a small blood sample which can be collected during a routine blood draw. Enzo plans to begin offering the assay to its clientele in March 2012.
You May Also Be Interested In
- UPDATE: ImmunoCellular (IMUC) Phase II Study Does Not Meet Survival Endpoint
- Enzo Biochem Schedules Teleconference to Discuss First Quarter Results Wednesday, December 11, 2013 at 8:30 AM E.T.
- Endocyte (ECYT) Announces Enrollment of First Patient in SMDC EC1456 Phase 1
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!